This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

Erin-Furr Stimming, AAN 2022: Valbenazine for chorea associated with Huntington disease – Results from the KINECT HD, phase 3 trial

4 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 30th 2022

Chorea is a common motor symptom of Huntington Disease (HD) which impacts motor function. Valbenazine, a potent and selective vesicular monoamine transporter 2 inhibitor, is being investigated for the treatment of chorea associated HD, and was approved for the treatment of tardive dyskinesia in the United States in 2017. Prof. Erin Furr-Stimming (McGovern Medical School, University of Texas, Health Science Centre, Houston, TX, USA) joins touchNEUROLOGY to discuss the KINECT-HD phase 3 trial, which evaluated the efficacy, safety, and tolerability of valbenazine for the treatment of chorea associated with HD.

Watch part 1 of this interview, where Prof. Erin Furr-Stimming also discusses the current treatment landscape for Huntington disease.

The abstracted entitled: ‘KINECT HD: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine for Chorea Associated with Huntington Disease (HD)‘ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.

Questions:

1. What were the aims, design and eligibility criteria of the KINECT-HD study? (0:23)
2. What were the efficacy outcome measures of the study and how well were they achieved? (1:15)
3. What were the safety findings, and what was the impact of valbenazine on suicidal ideation in the study population? (3:39)

Disclosures: Erin Furr-Stimming receives indirect grant/research support from HSG provided by NBI to UTHealth for her role as principal investigator on the Kinect-HD study, and no direct grant/research support remuneration from UniQure, CHDI, HDSA, Cures within Reach, Prilennia, and Roche/Genetech.

Support:  Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup